Sarepta Therapeutics (SRPT)
Develops Duchenne muscular dystrophy medicines and genetic therapies for rare diseases.
$19.42
vs last close−1.39 (−6.66%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 104.68% | 110.57M shares | |
|---|---|---|---|
| 348 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 5.45% | 5.76M shares | |
| 16 holders · as of Sep 8, 2026 | |||
| Adds to | 110.13% | ||
105.63M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.13%; nothing is left for Other.
13F, as of Jun 30, 2026
348 holders · 110.57M shares · 49 new positions · 151 increased · 118 reduced · 66 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 18.99M | 17.98% | +4.24M | Aug 7, 2026 |
| State Street Corp | 8.92M | 8.44% | +2.30M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.38M | 7.93% | +1.74M | Aug 13, 2026 |
| Two Sigma Investments, LP | 4.60M | 4.35% | +5.5K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.59M | 4.35% | +13.5K | Aug 13, 2026 |
| First Trust Advisors LP | 4.37M | 4.13% | +230.2K | Aug 11, 2026 |
| AQR Capital Management LLC | 4.33M | 4.10% | −2.11M | Aug 14, 2026 |
| Geode Capital Management, LLC | 2.77M | 2.62% | +783.0K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.60% | 13.23M | 13G | Jan 21, 2026 |
| State Street Corporation | 8.40% | 8.92M | 13G | Aug 7, 2026 |
| AQR Capital Management, LLC | 7.73% | 8.10M | 13G | Feb 13, 2026 |
| Vanguard Portfolio Management | 6.43% | 6.75M | 13G | Apr 29, 2026 |
| Vanguard Capital Management | 5.11% | 5.37M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 12, 2026 | Stephen Mayodirector | Sale | 7,239 | $17.02 | 1,765 |
| Dec 16, 2025 | Ian Michael Estepanofficer: Chief Operating Officer | Sale | 13,187 | $22.31 | 193,300 |
House and Senate disclosures
Not reported.